Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05050305
Other study ID # 20-551
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date March 2024
Est. completion date December 2, 2027

Study information

Verified date July 2023
Source Dana-Farber Cancer Institute
Contact Clifton Mo, MD
Phone 617-632-4167
Email Clifton_Mo@DFCI.HARVARD.EDU
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research is being done to test whether the investigational drug marizomib is safe and effective when used in combination with standard of care drugs for the treatment of multiple myeloma.


Description:

This is a Phase 2 single-arm study, incorporating two cohorts and using the combination of marizomib plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM) patients and in RRMM patients with CNS involvement. This research study involves a three drug chemotherapy regimen which includes taking the study drug marizomib, as well as pomalidomide and dexamethasone. The U.S. Food and Drug Administration (FDA) has not approved marizomib as a treatment for any disease. The U.S. Food and Drug Administration (FDA) has approved pomalidomide and dexamethasone as a treatment option for multiple myeloma. The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. As the study is looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have multiple myeloma, not everyone who participates in this research study will receive the same dose of the study drug. The dose received will depend on the number of participants who have been previously enrolled in the study and how well participants have tolerated their doses. Participants will receive study treatment for as long as participants do not have serious side effects and their disease does not get worse. It is expected that about 48 people will take part in this research study. Bristol-Myers Squibb is supporting this research study by providing funding and study drug.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date December 2, 2027
Est. primary completion date December 2, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Previously diagnosed with MM based on standard IMWG criteria and currently requires treatment. - Patients in the CNS-involved cohort must have CNS involvement of MM as defined by meningeal myelomatosis and/or radiological evidence of leptomeningeal disease and/or intracranial plasmacytoma involving brain parenchyma. - Patients in the CNS-involved cohort must have received at least one or more previous lines of therapy including an IMiD and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. - Patients in the RRMM cohort must have received at least two or more previous therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. - Patients in the RRMM cohort must have measurable disease defined as at least one of the following: - Serum M protein = 0.5 g/dL (=5 g/L) - Urine M protein =200 mg/24 hours - Serum free light chain (FLC) assay: Involved FLC assay =10 mg/dL (=100 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65) - Screening Laboratory evaluations within the following parameters - Absolute neutrophil count (ANC) = 1,000 cells/dL (1.0 x 109/L) (Growth factors cannot be used within 14 days before first drug administration) - Platelet count = 75,000 cells/dL (75 x 109/L) (without transfusions required during the 14 days prior to initiation of therapy) - Hemoglobin = 8.0 g/dl (RBC transfusions are permitted) - Total Bilirubin = 1.5 X upper limit of normal (ULN) (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) - AST (SGOT) and ALT (SGPT) = 3.0 x ULN - Calculated creatinine clearance = 45 mL/min - ECOG performance status =2 (Karnofsky =60%, see Appendix A) - All study participants must be registered into the mandatory POMALYST REMS® program, and be willing and able to comply with the requirements of the POMALYST REMS® program. - Females of reproductive potential must adhere to the scheduled testing as required in the POMALYST REMS® program. - Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin). - Patients have given voluntary written informed consent before performance of any study-related procedures not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care. - Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - Prior exposure to marizomib. and primary refractoriness to pomalidomide or a pomalidomide combination. Prior pomalidomide exposure is permitted but patients must have shown tolerance (defined as no grade 3 or greater non-hematologic toxicity), as well as responsiveness to pomalidomide-based therapy (defined as MR or better). - Diagnosed or treated for another malignancy within 3 years prior to enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low risk prostate cancer after curative therapy/watchful waiting. - Known GI disease or GI procedure that could interfere with the oral absorption of pomalidomide including difficulty swallowing. - Systemic treatment, within 14 days before the first dose of pomalidomide, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort. - Peripheral neuropathy = Grade 3, or Grade 2 with pain on clinical examination during the screening period. - Any medical or psychiatric illness that in the investigator's opinion, would impose excessive risk to the patient or would adversely affect his/her participating in this study. - Current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, Grade 3 thromboembolic event or myocardial infarction within the past 6 months. - The following therapies within the stated time frames prior to initiation of therapy: previous cytotoxic therapies, including cytotoxic investigational agents, for MM within 3 weeks; IMiDs, PIs, corticosteroids, other approved therapeutics and monoclonal antibodies (Mabs) within 2 weeks; and investigational therapies within 4 weeks. Please note consideration of the interval for investigational agents from already approved classes of drug in MM (e.g. Cell-Mods, Mabs) can be considered on a case by case basis with the PI. Prior peripheral stem cell transplant within 12 weeks and the use of live vaccines within 30 days. - Prior allogeneic stem cell transplantation with active graft-versus-host-disease (grade 2 or greater). - Prior major surgical procedure or radiation therapy within 4 weeks of initiation of therapy (this does not include limited course of radiation used for management of bone pain within 7 days of initiation of therapy). - Daily requirement for corticosteroids equivalent to > 10 mg/day prednisone, except for inhalation corticosteroids, for the RRMM cohort. For patients with CNS involvement who require a higher dose of corticosteroids for control of vasogenic edema (e.g. 16 mg/day dexamethasone), eligibility will be determined on a case-by-case basis after discussion with the PI. - Any > Grade 1 adverse reaction unresolved from previous treatments according to the National Cancer Institute - Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTC AE v.5.0). The presence of alopecia any grade or peripheral neuropathy = Grade 2 without pain is allowed. - Concurrent symptomatic amyloidosis or plasma cell leukemia. - POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes). - Known active infection requiring parenteral or oral anti-infective treatment within 7 days of start of therapy. - Known human immunodeficiency virus or active hepatitis C viral infection. - Active hepatitis B viral infection (defined as HBsAg+). - Patients with prior hepatitis B vaccine are permitted (defined as HBsAg-, Anti-HBs+, Anti-HBc-). - Non-active hepatitis B (HBsAg-, Anti-HBs+, Anti-HBc+) may be enrolled at the discretion of the investigator after consideration of risk of reactivation. - Pregnant or breast-feeding females. - Participants who are receiving any other investigational agents. - History of erythema multiforme or severe hypersensitivity to prior IMiD's®. - Inability to tolerate thromboprophylaxis. - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Known hypersensitivity to thalidomide or lenalidomide or other drugs included in this study. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide, pomalidomide or similar drugs. -

Study Design


Intervention

Drug:
Marizomib
Intravenous Infusion
Pomalidomide
Taken orally
Dexamethasone
Taken orally

Locations

Country Name City State
United States Dana-Farber Cancer Institute Boston Massachusetts
United States Massachusetts General Hospital Cancer Center Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Dana-Farber Cancer Institute Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Tolerated Dose (MTD) Safety Run-In MTD is defined as the highest dose level where no patients (of the 6 treated) develop a dose limiting toxicity (DLT) From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years
Primary Dose Limiting Toxicity (DLT) Toxicity summaries will be stratified by dose level, grade, and treatment attribution From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years
Primary The number and proportion of adverse events, graded as defined by CTCAE version 5.0. CTCAE version 5.0. From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years
Primary Overall response rate (ORR) Assessed using the updated International Myeloma Working Group Response Criteria (IMWG) (Rajkumar 2011). From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years
Secondary Time to response (TTR) Assessed using the updated International Myeloma Working Group Response Criteria (IMWG) (Rajkumar 2011). From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years
Secondary Progression free survival (PFS) Assessed using the updated International Myeloma Working Group Response Criteria From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first. up to 5 years
Secondary Duration of response (DOR) Assessed using the updated International Myeloma Working Group Response Criteria (IMWG) (Rajkumar 2011). From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 5 years
Secondary Overall survival (OS) Assessed using the updated International Myeloma Working Group Response Criteria From date of enrollment until date of death from any cause, up to 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1